Mark A. Moyad

2.4k total citations
119 papers, 1.6k citations indexed

About

Mark A. Moyad is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mark A. Moyad has authored 119 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Surgery, 23 papers in Pulmonary and Respiratory Medicine and 21 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mark A. Moyad's work include Cancer, Lipids, and Metabolism (21 papers), Nutritional Studies and Diet (20 papers) and Complementary and Alternative Medicine Studies (16 papers). Mark A. Moyad is often cited by papers focused on Cancer, Lipids, and Metabolism (21 papers), Nutritional Studies and Diet (20 papers) and Complementary and Alternative Medicine Studies (16 papers). Mark A. Moyad collaborates with scholars based in United States, Australia and Germany. Mark A. Moyad's co-authors include Peter R. Carroll, Gregory S. Merrick, Kenneth J. Pienta, Kent E. Wallner, Robert W. Galbreath, Larry E. Robinson, James E. Montie, Julie M. Kittelsrud, Stuart G. Reeves and Edward Adamovich and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The American Journal of Medicine.

In The Last Decade

Mark A. Moyad

115 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark A. Moyad United States 25 426 280 279 276 234 119 1.6k
Lin Zhu China 18 272 0.6× 243 0.9× 315 1.1× 468 1.7× 375 1.6× 74 1.8k
Anne Ballinger United Kingdom 26 330 0.8× 169 0.6× 742 2.7× 348 1.3× 312 1.3× 58 2.5k
Kathryn M. Wilson United States 31 982 2.3× 573 2.0× 262 0.9× 557 2.0× 150 0.6× 101 2.9k
Ivan Tancevski Austria 25 230 0.5× 132 0.5× 371 1.3× 434 1.6× 324 1.4× 81 1.9k
Hassan Argani Iran 25 194 0.5× 84 0.3× 289 1.0× 336 1.2× 271 1.2× 113 1.8k
Min‐Ae Song United States 26 213 0.5× 199 0.7× 132 0.5× 766 2.8× 97 0.4× 70 1.9k
Esteban Orenes‐Piñero Spain 26 153 0.4× 215 0.8× 230 0.8× 751 2.7× 128 0.5× 90 1.9k
Michele Malaguarnera Italy 23 156 0.4× 108 0.4× 357 1.3× 695 2.5× 291 1.2× 56 2.2k
Lin Ding China 26 285 0.7× 70 0.3× 252 0.9× 528 1.9× 296 1.3× 63 2.0k
Kei Nakajima Japan 23 146 0.3× 122 0.4× 376 1.3× 581 2.1× 452 1.9× 128 2.2k

Countries citing papers authored by Mark A. Moyad

Since Specialization
Citations

This map shows the geographic impact of Mark A. Moyad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Moyad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Moyad more than expected).

Fields of papers citing papers by Mark A. Moyad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Moyad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Moyad. The network helps show where Mark A. Moyad may publish in the future.

Co-authorship network of co-authors of Mark A. Moyad

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Moyad. A scholar is included among the top collaborators of Mark A. Moyad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Moyad. Mark A. Moyad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Moyad, Mark A. & Kwangsung Park. (2012). What do most erectile dysfunction guidelines have in common? No evidence-based discussion or recommendation of heart-healthy lifestyle changes and/or Panax ginseng. Asian Journal of Andrology. 14(6). 830–841. 15 indexed citations
3.
Moyad, Mark A. & Laurence Klotz. (2011). Statin Clinical Trial (REALITY) for Prostate Cancer: an Over 15-Year Wait is Finally Over Thanks to a Dietary Supplement. Urologic Clinics of North America. 38(3). 325–331. 6 indexed citations
4.
Moyad, Mark A.. (2011). The Optimal Male Health Diet and Dietary Supplement Program. Urologic Clinics of North America. 39(1). 89–107. 4 indexed citations
5.
Moyad, Mark A.. (2011). Heart Health = Urologic Health and Heart Unhealthy = Urologic Unhealthy: Rapid Review of Lifestyle Changes and Dietary Supplements. Urologic Clinics of North America. 38(3). 359–367. 5 indexed citations
6.
Moyad, Mark A., Larry E. Robinson, Edward T. Zawada, et al.. (2010). Immunogenic Yeast-Based Fermentate for Cold/Flu-like Symptoms in Nonvaccinated Individuals. The Journal of Alternative and Complementary Medicine. 16(2). 213–218. 28 indexed citations
7.
Moyad, Mark A., Larry E. Robinson, Julie M. Kittelsrud, et al.. (2009). Immunogenic yeast-based fermentation product reduces allergic rhinitis-induced nasal congestion: a randomized, double-blind, placebo-controlled trial. Advances in Therapy. 26(8). 795–804. 31 indexed citations
8.
Moyad, Mark A.. (2008). Conventional, complementary, and alternative options for seasonal allergies.. PubMed. 28(3). 227–8. 2 indexed citations
9.
Moyad, Mark A., et al.. (2007). Alternative medicine utilization by African Americans and improving life expectancy: is there a correlation?. PubMed. 27(5). 449–50, 459. 1 indexed citations
10.
Moyad, Mark A.. (2007). What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer?. PubMed. 27(3). 256–7. 3 indexed citations
11.
Moyad, Mark A.. (2005). An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: Part II. Urologic Oncology Seminars and Original Investigations. 23(1). 36–48. 65 indexed citations
12.
Moyad, Mark A. & Gregory S. Merrick. (2005). Statins and cholesterol lowering after a cancer diagnosis: Why not?. Urologic Oncology Seminars and Original Investigations. 23(1). 49–55. 10 indexed citations
13.
Moyad, Mark A., et al.. (2004). Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urologic Clinics of North America. 31(2). 249–257. 20 indexed citations
14.
Moyad, Mark A.. (2004). Heart healthy equals prostate healthy equals statins: the next cancer chemoprevention trial. Part II. Current Opinion in Urology. 15(1). 7–12. 11 indexed citations
15.
Moyad, Mark A. & Peter R. Carroll. (2004). Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention?. Urologic Clinics of North America. 31(2). 289–300. 21 indexed citations
16.
Moyad, Mark A., James H. Barada, Tom F. Lue, et al.. (2004). Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part II. Urologic Clinics of North America. 31(2). 259–273. 25 indexed citations
17.
Moyad, Mark A.. (2003). Bladder cancer prevention. Part I: what do I tell my patients about lifestyle changes and dietary supplements?. Current Opinion in Urology. 13(5). 363–378. 11 indexed citations
18.
Moyad, Mark A.. (2003). Osteoporosis: a rapid review of risk factors and screening methods. Urologic Oncology Seminars and Original Investigations. 21(5). 375–379. 40 indexed citations
19.
20.
Moyad, Mark A.. (2002). Lifestyle/dietary supplement partial androgen suppression and/or estrogen manipulation. Urologic Clinics of North America. 29(1). 115–124. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lin Zhu Breakdown of academic impact, for papers by Anne Ballinger Breakdown of academic impact, for papers by Kathryn M. Wilson Breakdown of academic impact, for papers by Ivan Tancevski Breakdown of academic impact, for papers by Hassan Argani Breakdown of academic impact, for papers by Min‐Ae Song Breakdown of academic impact, for papers by Esteban Orenes‐Piñero Breakdown of academic impact, for papers by Michele Malaguarnera Breakdown of academic impact, for papers by Lin Ding Breakdown of academic impact, for papers by Kei Nakajima
Rankless by CCL
2026